Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Crucell Terug naar discussie overzicht

Draadje HIV/AIDS

252 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 juli 2006 13:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    DJ Annan: 9 Cos To Help Provide Acess To HIV/AIDS Treatment

    07/25/2006
    Dow Jones News Services
    (Copyright © 2006 Dow Jones & Company, Inc.)


    UNITED NATIONS (AP)--Nine pharmaceutical and diagnostic companies have pledged to try to help meet the goal of providing universal access to HIV/AIDS prevention and treatment by 2010, Secretary-General Kofi Annan said Monday.

    Annan issued a statement after a private meeting between senior U.N. officials and top executives of the nine leading companies from the United States, Britain, India and South Africa to discuss ways to step up the response to the AIDS epidemic.

    "I am pleased that the companies I met with today pledged to continue their efforts, in line with international commitments toward the goal of being as close as possible to universal access by 2010," he said.

    Annan said the companies have made a commitment to the following measures:

    - To make their products more affordable, accessible and appropriate for use in low- and middle-income countries;

    - To register their HIV medications and diagnostic tools as widely as possible, including in developing countries;

    - To give greater priority to research and development of HIV medicines and diagnostic tools for children;

    - To increase investment in research and development of new HIV-related medications and diagnostic tools including vaccines and female-controlled technologies such as microbicides;

    - To continue to make arrangements with third-party manufacturers for licenses and the transfer of technology to make HIV medications and diagnostic tools more affordable and accessible.

    The United Nations agreed to devise, promote and update guidelines on HIV/AIDS diagnosis, treatment and product quality for adults and children. It will also step up its work with all partners to ensure sustained political leadership, adequate resources and better access to voluntary testing and counseling, Annan said.

    He said all participants stressed the importance of intellectual property to encourage research and development, and they agreed that strengthening health care systems is essential to expand access to treatment and advanced prevent efforts.

    "Progress on all these fronts is essential if we are to win the fight against HIV/AIDS - the greatest challenge of our generation," Annan said.

    Participants at the meeting were Aspen Pharmacare of South Africa, Britain's GlaxoSmithKline and three Indian companies - Aurobindo Pharma Ltd., Hetero Drugs Ltd., and Raxbaxy Laboratories Ltd. Four U.S. companies also took part, Becton Dickinson, Bristol-Myers Squibb, Johnson & Johnson, and Merck & Co.


    Dirk
  3. diederique 25 juli 2006 13:58

    • diederique

      Lid sinds: 01 mrt 2004

      Laatste bezoek: 04 apr 2024

    • Aanbevelingen

      Ontvangen: 913

      Gegeven: 218

    •    Aantal posts: 8.547

    Met Gates' geld zoeken naar vaccin
    LEON WILLEMS

    Miljardairsechtpaar Gates schenkt $ 287 mln voor onderzoek naar een HIV-vaccin. Onderzoekers uit negentien landen moeten speuren naar innovatieve benaderingen voor vaccinonderzoek. Welke benaderingen zijn dat en welke zijn volgens deskundigen veelbelovend?

    Haast maken, dat willen Bill en Melinda Gates van de gelijknamige stichting. Ondanks vijfentwintig jaar onderzoek is er nog steeds geen vaccin dat aidsbesmetting kan voorkomen.

    Het is niet zo vreemd dat Gates een impuls wil geven. Deskundigen verwachten dat het nog wel tien jaar kan duren voordat er een aidsvaccin beschikbaar is. Tien jaar is zeer lang als je een epidemie wilt bestrijden.

    Indien er geen vaccin gevonden wordt, zullen in het jaar 2020 alleen al in zuidelijk Afrika ruim 2,5 miljoen aidsdoden te betreuren zijn, zo becijferde de wereldgezondheidsorganisatie WHO onlangs. Tegen die tijd heeft de epidemie inmiddels ook grote delen van Zuidoost-Azië en Oost-Europa in haar dodelijke greep. Wereldwijd lijden nu circa 40 miljoen mensen aan de ongeneeslijke ziekte. Vorig jaar stierven 3 miljoen mensen aan aids volgens cijfers van de WHO.

    Aids wordt veroorzaakt door het Humaan Immunodeficiëntie Virus (HIV). Het virus breekt het afweersysteem af. Daardoor wordt het lichaam vatbaar voor allerlei infecties en bepaalde vormen van kanker. Infectieremmers die het ziekteproces vertragen en de levensverwachting laten toenemen, zijn nuttig maar ze pakken de oorzaak van het probleem niet aan.

    De jongste donatie van Gates is erop gericht om meer coördinatie te brengen in de wereldwijde onderzoeksinspanningen. Tot nu toe is onderzoek te kleinschalig en versnipperd. Daarom verdeelt de Gates-stichting het geld over zestien consortia van onderzoeksinstituten en testlaboratoria. Die moeten verkennen wat de meest innovatieve benaderingen zijn voor onderzoek naar een aidsvaccin. Nieuwe vaccinkandidaten worden getest en testresultaten worden gedeeld met andere deelnemende onderzoeksconsortia. Zo kunnen de veelbelovende kandidaten met voorrang verder worden ontwikkeld.

    Vijf van de onderzoeksconsortia gaan op zoek naar een vaccin dat doeltreffende antilichamen kan opwekken (zie inzet). Tot nu toe is slechts een handvol zogeheten neutraliserende antilichamen voor HIV ontdekt. Dat moeten er flink meer worden. De moeilijkheid dergelijke antistoffen op te wekken wordt door wetenschappers gezien als een van de grootste obstakels voor het maken van een aidsvaccin.

    Een groep van zes instituten gaat onderzoek doen hoe menselijke cellen immuun kunnen worden gemaakt tegen besmetting met HIV. Bestaande vaccinkandidaten vertonen nog te grote tekortkomingen, zo oordeelt het deskundigenteam dat Gates bijstaat in de aanpakkeuze van een donateursproject.

    Maar wat maakt een aidsvaccin vinden zo moeilijk? 'Een fundamenteel probleem is het ontwikkelen van een preventief vaccin', legt Joep Lange uit. Hij is hoogleraar inwendige geneeskunde en directeur van het Center for Poverty-related Communicable Diseases dat is verbonden aan het Amsterdam Medisch Centrum. 'Daarvoor heb je neutraliserende antistoffen nodig', zegt Lange. 'Wetenschappers zijn jarenlang misleid in hun zoektocht omdat antistoffen die in het laboratorium wel een neutraliserende werking toonden dat niet deden in het menselijke lichaam. De antistoffen konden niet goed bij de plek waar ze moesten zijn.' Bovendien kent het virus veel verschillende gedaanten. 'Haast geen HIV-stam lijkt op de ander', zegt Lange.

    De aanpak van gestructureerd samenwerkende onderzoeksconsortia, zoals Gates beoogt, is niet nieuw. 'Wel de grootschaligheid is vernieuwend', weet Lange. Hij herinnert zich hoe enkele jaren geleden het International Aids Vaccin Initiative de knuppel in het hoenderhok gooide. 'Zij wilden een systematische aanpak in plaats van academisch geneuzel. Zij kregen ook financiering. Grote onderzoeksinstituten werden daar knap nerveus van.'

    Wat zijn volgens onderzoeker Lange de meest belovende onderzoeksporen? 'Wisten we dat maar', antwoordt hij. Het International Aids Vaccin Initiative bracht deskundigheid over neutraliserende antistoffen bij elkaar. Daar moet de oplossing vandaan komen. De vaccins die we nu hebben wekken cellulaire weerstand op maar niet de bescherming die neutraliserende antistoffen bieden.'

    De hamvraag is natuurlijk welke antistoffen het HIV-virus neutraliseren. Lange denkt dat onderzoek zich op de korte termijn moet richten op vaccinaire combinaties die cellulaire weerstand opwekken, bijvoorbeeld een combinatie van een DNA-vaccin en een pokvirus. 'Zo'n vaccin zal waarschijnlijk niet veel bescherming geven tegen besmetting maar zou het virus er voor langere tijd onder kunnen houden. Het ontwikkelen van een vaccin dat neutraliserende antistoffen opwekt en echt bescherming tegen infectie geeft, is langetermijnwerk.'

    technologie@fd.nl
  4. [verwijderd] 14 augustus 2006 13:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    =DJ Study Finds 4-Drug Treatment No Better Than 3 For HIV

    08/14/2006
    Dow Jones News Services
    (Copyright © 2006 Dow Jones & Company, Inc.)


    By Peter Loftus
    Of DOW JONES NEWSWIRES

    (This article was originally published Sunday)


    The addition of a GlaxoSmithKline PLC (GSK) HIV drug to a three-drug regimen for initial treatment of HIV infection provided no additional benefit compared with the three-drug treatment, a study concluded.

    The study, whose results were to be presented Sunday at the International AIDS Conference in Toronto, involved 765 HIV-infected patients who hadn't been treated before and was conducted between March 2001 and March 2005. About half were given three drugs: zidovudine, lamivudine and efavirenz. Glaxo sells the first two under the brands Retrovir and Epivir, respectively, while Bristol-Myers Squibb Co. (BMY) sells the third under the brand Sustiva.

    The other half of the patients were given the three drugs plus abacavir, which Glaxo sells under the brand Ziagen.

    The study found there was no significance difference in effectiveness between the two regimens. "High rates of virologic suppression achieved in this study support current guidelines that recommend" the three-drug regimen for initial treatment of HIV infection, the authors wrote in a study to be published in the Aug. 16 issue of the Journal of the American Medical Association.

    Adding the fourth drug, abacavir, "provided no additional benefit," wrote the authors, who included researchers at the Weill Medical College of Cornell University in New York. Some of the researchers have received grants and compensation from the drug companies. The study was funded by the National Institutes of Health, with medications supplied by the manufacturers.

    Another study presented at the AIDS conference suggested that using a single drug with a booster, instead of a standard three-drug regimen, may be an effective maintenance therapy for some HIV patients.

    This small pilot study involved 34 HIV-infected patients whose viral levels had already been reduced by using a regimen of at least three drugs. They were then switched to atazanavir, which is sold by Bristol under the brand Reyataz, and given a booster known as ritonavir, sold as Norvir by Abbott Laboratories (ABT). After 24 weeks, 91% of the patients had continued suppressed viral levels, according to the study, which also is being published in JAMA.

    The study's authors said the preliminary data suggest that a "simplified maintenance therapy" might be able to maintain virologic suppression in carefully selected HIV patients. But the authors wrote that a larger, randomized study is needed to confirm this. The authors have received grants and compensation from Bristol-Myers and Abbott; the study was funded by NIH, with drugs supplied by the manufacturers.

    - Peter Loftus; Dow Jones Newswires; 215-656-8289; peter.loftus@dowjones.com


    Dirk
  5. diederique 15 augustus 2006 22:57

    • diederique

      Lid sinds: 01 mrt 2004

      Laatste bezoek: 04 apr 2024

    • Aanbevelingen

      Ontvangen: 913

      Gegeven: 218

    •    Aantal posts: 8.547

    Experimental HIV drug 'helps control virus'

    12.59am Monday August 14, 2006


    TORONTO - An experimental HIV drug in a new class called integrase inhibitors helps control the virus well combined with other drugs commonly used in AIDS cocktails, its maker Merck and Co. has reported.

    The findings, to be presented at an international AIDS meeting, offer a potential new weapon in the growing armoury of drugs that fight HIV. The drug mixtures can keep HIV patients healthy for years, although they are not a cure.

    Merck said the drug, known by its experimental name MK-0518, worked as well as older drugs to suppress the AIDS virus when combined with Gilead Sciences' tenofovir, known commercially as Viread and GlaxoSmithkline's lamivudine, sold under the brand name Epivir.

    They compared the new drug with a similar cocktail using Bristol Myer Squibb's efavirenz, sold under the brand names Sustiva and Stocrin. For the study, 198 HIV-infected patients took one or the other mixture for 24 weeks.

    Both combinations lower viral load - the amount of the virus be found in blood. Suppressing the virus limits the damage it can do to a patient's immune system.

    "This early study showed a rapid and significant reduction in viral load up to 24 weeks with MK-0518," Dr. Martin Markowitz of the Aaron Diamond AIDS Research Centre in New York, who led the study, said in a statement.

    "This study should lend further insight into the potential of HIV integrase inhibitors as a new and exciting class of antiretroviral agents."

    There are several classes of HIV drugs, also known as antiretroviral drugs. Each class attacks the virus at a different point in its cycle of replication.

    Combining the drugs in a cocktail suppresses the virus even more, but eventually the virus in a patient's body escapes the effects of drugs so new approaches and combinations are needed to control it.

    When the human immunodeficiency virus infects a cell, usually an immune system cell called a T-cell, it attaches to the cell, pierces it and inserts its own genetic material.

    The viral DNA reprogrammes the cell, in essence hijacking it, and forces it to produce copy after copy of the virus, which it pumps into the blood to infect other cells.

    The integrase inhibitors stop the insertion of the HIV viral DNA into human DNA, shutting down the virus factory.

    Other HIV drugs target other enzymes involved in this hijacking process.

    Several companies are working on integrase inhibitors but none has been approved yet.

    - REUTERS


  7. pim f 16 augustus 2006 11:21

    • pim f

      Lid sinds: 29 sep 2004

      Laatste bezoek: 08 mei 2024

    • Aanbevelingen

      Ontvangen: 865

      Gegeven: 773

    •    Aantal posts: 4.094

    Future seen promising for AIDS vaccine

    By Maggie Fox, Health and Science Correspondent 12 minutes ago

    TORONTO (Reuters) - There is no vaccine against AIDS and none of the dozens of vaccines being tested is likely to completely protect people from the deadly virus, but the future looks bright for AIDS vaccine development, researchers said on Tuesday. Scientists will learn from the vaccines now being tested, and the developing world, hardest hit by HIV, is starting to produce its own vaccine effort, said Dr. Seth Berkley, head of the nonprofit International AIDS Vaccine Initiative.

    "An AIDS vaccine is the only tool that can end the pandemic," Berkley told a news conference to launch a biennial report on vaccines at the 16th International AIDS Conference in Toronto. "All evidence suggests that a vaccine is possible. There is progress being made. It's slow but it's steady," he added. "To me, we are about to enter a renaissance in AIDS vaccine research."

    Yet Berkley said only two AIDS vaccine candidates are in advanced human trials -- one made by Merck and Co. and another by Sanofi-Aventis SA. "The next major milestone for the field is likely to be the Merck result, which is a test for cellular immunity," Berkley said. Berkley and others do not expect the Merck vaccine will protect against disease in the way, for instance, a measles vaccine does.

    The AIDS virus infects more than 39 million people globally, more than 60 percent of them in sub-Saharan Africa. It kills more than 4 million people every year and has killed 25 million people since it was identified in the 1980s. It is difficult to vaccinate against because the virus infects the very immune system cells that are usually stimulated by a vaccine. "This is probably the toughest adversary that has ever been out there for vaccine development," Berkley said.

    Most vaccine stimulate antibodies, immune system proteins that mark enemy invaders for destruction. Vaccine researchers believe that a good AIDS vaccine will have to stimulate both antibodies and so-called cellular immunity, which is the job of T-cells, dendritic cells and other immune cells.

    Berkley hopes results of how well the Merck vaccine works will be available in 2008. If it reduces infection rates by even a little, scientists can study the volunteers and see just what successful aspects could be used as clues for further research. If it does not work at all, whole new approaches will have to be pursued.

    Even a partially effective vaccine could be useful, said Stephen Lewis, the United Nations delegate to Africa for AIDS. "I think it's fair to say ... even a modestly effective vaccine could cut the number of new infections by one-third over a decade, saving tens of millions of lives," Lewis told the news conference.

    news.yahoo.com/s/nm/20060816/ts_nm/ai...
  11. forum rang 4 Opstapelen 19 augustus 2006 14:48

    • Opstapelen

      Lid sinds: 23 okt 2005

      Laatste bezoek: 09 mei 2024

    • Aanbevelingen

      Ontvangen: 1400

      Gegeven: 435

    •    Aantal posts: 4.888

    Beste Flosz
    Misschien moet jij je mailadres wereldkundig maken en te beginnen hier op het forum.
    Mocht er een speurneus zijn, dan kan hij/zij eerst even jouw archief raadplegen ten einde zeker te weten of het hier om de laatste updates gaan of de postings(meestal door jouw) al gedaan zijn.
    (hele dikke lol)
    Erik
  12. [verwijderd] 22 augustus 2006 13:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    *DJ Vical Launches Phase I Trial Of HIV-Related Vaccine>VICL

    08/22/2006
    Dow Jones News Services
    (Copyright © 2006 Dow Jones & Company, Inc.)


    (MORE TO FOLLOW) Dow Jones Newswires

    08-22-06 0730ET

    Copyright (c) 2006 Dow Jones & Company, Inc.

    *DJ Vical Launches Phase I Trial Of 'Prime Boost' Vaccine>VICL

  13. [verwijderd] 22 augustus 2006 14:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Vical DNA Delivery Technology Enters Clinical Trial for Therapeutic HIV Vaccine

    SAN DIEGO, Aug. 22 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today the initiation of a National Institutes of Health (NIH) sponsored Phase 1 clinical trial of a "prime-boost" vaccine approach designed to prevent or control disease in patients already infected with HIV. The trial involves priming an immune response with multiple doses of a plasmid DNA vaccine, based on Vical's proprietary DNA delivery technology, and boosting the response with a single dose of adenoviral vector vaccine given at a later date.

    The vaccine was developed by scientists at the Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and was manufactured by Vical. The vaccine incorporates HIV genetic material from the three most globally important HIV subtypes, clades A, B and C, which are involved in about 85 percent of all HIV infections around the world. The same vaccine is currently being tested in a preventive setting through a multinational Phase 2 trial initiated in October 2005. Results from a Phase 1 trial in HIV-uninfected subjects showed that the prime-boost approach was well tolerated and effective in producing potent cellular and antibody immune responses, including specific responses against each of the HIV subtypes. The new Phase 1 trial is the first therapeutic application of a "prime/boost" vaccine against HIV in the VRC program.

    "Antiviral drugs have dramatically improved the outlook for HIV-infected individuals," said Vijay B. Samant, Vical's President and Chief Executive Officer, "but complicated treatment regimens, serious side effects and increasing drug resistance call for better long-term solutions. A post-infection vaccine that would allow the immune system to suppress viral loads could provide significant benefits both to prevent disease symptoms in the individual and potentially to reduce disease transmission between individuals. We are excited that our collaborators at the VRC have advanced into human testing with this novel vaccine application."

    The vaccine used in the Phase 1 trial incorporates parts of four HIV genes. Three of these vaccine components are modified versions of HIV genes called gag, pol and nef, synthetically made based on sequence from clade B, the subtype that predominates in Europe and North America. The fourth vaccine component is a modified version of the HIV gene named env. The env gene codes for a protein on the outer coat of the virus that allows it to recognize and attach to human cells. VRC scientists were the first to combine modified env from clades A and C, which are the most common in Africa and parts of Asia, with the modified env gene from clade B. The study is being conducted at the NIH Clinical Center. The trial is double-blinded and placebo-controlled, and will evaluate safety, tolerability and immune response. Subjects will continue highly active antiretroviral therapy (HAART) throughout the trial.

    Vical has produced multiple DNA vaccines for the VRC against infectious disease targets including Ebola, severe acute respiratory syndrome (SARS), and West Nile virus, all of which have advanced into Phase 1 clinical trials over the past three years.

    D.


  14. [verwijderd] 22 augustus 2006 19:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    DJ GenVec Says NIH Plans Human Trials Of HIV Treatment

    08/22/2006
    Dow Jones News Services
    (Copyright © 2006 Dow Jones & Company, Inc.)

    DOW JONES NEWSWIRES

    GenVec Inc. (GNVC) said Tuesday that the first human therapeutic clinical trial for a potential HIV vaccine involving the company's adenoviral-vector technology will be conducted by the National Institutes of Health's vaccine research center.

    The 15 HIV-positive patients will first be treated with a DNA "prime" vaccine, then will be given a second, "boost" vaccine, which was developed using GenVec's DNA carrier-based technology.

    Shares of GenVec, Gaithersburg, Md., were up 12% Tuesday, recently trading at $1.15, up 12 cents from Monday's close.

    -Carolyn Pritchard; 415-439-6400; AskNewswires@dowjones.com


    Dirk
  15. [verwijderd] 22 augustus 2006 19:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The Aids vaccine field - Major players.

    PHARMACEuTICAL CoMPANIES

    GlaxoSmithKline

    GlaxoSmithKline (www.gsk.com) has focused its AIDS
    vaccine development efforts on recombinant protein
    vaccine candidates and has conducted trials of a gp120
    plus NefTat fusion protein. In addition, GSK has an
    active program in the development of adjuvants for
    recombinant protein vaccines. GSK has recently diversified its portfolio to include nonhuman primate adenovirus and measles vectors as vaccine candidates.

    Merck

    The Merck (www.merck.com) AIDS vaccine research
    program is focusing on replication-defective recombinant adenovirus vectors. In collaboration with HVTN,
    its lead candidate has begun a collaborative Phase IIb
    study at both Merck and HVTN clinical trial sites in
    North and South America, the Caribbean, and Australia. Merck has also tested a series of DNA candidates in
    trials, evaluating copolymer and alum adjuvants aimed
    at enhancing the immunogenicity of DNA vaccines in
    humans. Finally, Merck has teamed with sanofi-aventis
    to evaluate a vaccination strategy of adenovirus vectors
    to prime and canarypox vectors to boost.

    sanofi–aventis

    Sanofi-aventis (http://en.sanofi-aventis.com) has focused
    its AIDS vaccine design efforts on optimizing candidate
    vaccines based on its proprietary position in recombinant viral vectors, specifically canarypox vectors, the
    most advanced of which are in Phase III clinical trials.

    BIoTECHNoLoGy CoMPANIES

    Wyeth
    (www.wyeth.com) has focused its AIDS vaccine
    research on DNA technology adjuvanted with IL-12,
    DNA followed by synthetic peptide boost, and vesicular
    stomatitis virus (VSV) as a live vaccine delivery vehicle.
    The VSV research program is in collaboration with Yale
    University. Wyeth has conducted clinical trials of DNA
    and peptide candidates.

    Advanced BioScience Laboratories
    (www.
    ablinc.com) is a biotechnology company that specializes in biomedical research with a focus on virology.
    ABL has entered into a multi year agreement with the
    National Institute of Allergy and Infectious Diseases,
    part of the National Institutes of Health, to perform
    preclinical development of promising HIV-1 vaccines
    and microbicides.

    AlphaVax
    (www.alphavax.com) is developing new
    vaccine technology with broad applications against
    infectious disease, cancer, and biodefense threats which
    have the potential to redefine vaccines and the role they
    play in medicine. AlphaVax uses a specialized viral
    vector system to make alphavirus replicon vaccines
    called alphavaccines, which have shown excellent protection in multiple models for infectious disease.

    Crucell
    (www.crucell.com) is a biotechnology company focused on research, development, production, and
    worldwide marketing of vaccines and antibodies that
    combat infectious diseases. The AdVac vectors, adenovirus serotypes 11 and 35, have shown promising results as
    vectors for AIDS vaccines in a series of studies by Crucell
    in collaboration with Harvard Medical School. Crucell
    has entered into an exclusive license agreement with IAVI
    to develop this technology and a cell line for the production of adenovector-based vaccines.

    GeoVax
    (www.geovax.com) is a biotechnology company developing vaccines for HIV-1 and other infectious
    agents. Successful Phase I clinical trials of a DNA vaccine
    have demonstrated the safety of this vaccine. Phase Ia/Ib
    trials to test various combinations of DNA and MVA
    AIDS vaccines in volunteers for safety and immonogenicity are planned for 2006.

    FIT Biotech
    (www.fitbiotech.com) is an innovative medical biotechnology company engaged in the
    development and commercialization of its proprietary
    Gene Transport Unit (GTU) technology and GTU
    product applications in DNA vaccination as well as
    in immuno-and gene therapies. FIT Biotech’s HIV
    DNA therapeutic vaccine candidate has advanced
    to a Phase II trial in collaboration with Chris Hani
    Baragwanath Hospital, Pediatric Research Centre,
    Soweto, South Africa.

    Maxygen
    (www.maxygen.com) is developing a
    preventive HIV vaccine. Its “MolecularBreeding”
    directed evolution platform generates novel HIV-1
    antigens potentially capable of inducing broad antibody responses to multiple strains of the HIV-1 virus.
    An SBIR award funds investigations into the effect on
    immunogenicity of secondary modifications to a specific
    HIV-1 envelope protein. A grant from the Department
    of Defense funds work to develop a high-throughput
    HIV vaccine screening platform.

    Mymetics
    (www.mymetics.com) is developing
    vaccines and therapies to combat AIDS. Its lead vaccine
    candidate combines the company’s HIV-1 gp41derived peptide antigen grafted onto virosomes. Previous
    research has demonstrated that virosome-based vaccine
    technology is able to elicit protective antibodies in
    various anatomical compartments, which may prevent
    HIV translocation across mucosal tissues.

    Targeted Genetics
    (www.targetedgenetics.com)
    is a biotechnology company focused on the development of innovative targeted molecular therapies.
    Targeted Genetics, in collaboration with IAVI, Columbus Children’s Research Institute, and Children’s
    Hospital of Philedelphia, is pursuing development
    of an AIDS vaccine, tgAAC09, a recombinant vaccine
    candidate that delivers select genes from HIV
    packaged within the capsid of an adeno-associated
    virus (AAV).

    Therion Biologics
    (www.therionbio.com) is engaged in the development of therapeutic vaccines
    for cancer and preventive vaccines for AIDS. Therion is
    developing a preventive AIDS vaccine based on the
    MVA pox virus vector for IAVI.

    Vical
    (www.vical.com) researches and develops bio-
    pharmaceutical products based on DNA delivery technol-
    ogies. In 2003, Vical entered into a subcontract agree-
    ment to manufacture bulk DNA vaccines for the VRC.

    Virax
    (www.virax.com.au) is an early-stage-devel-
    opment biopharmaceutical company focusing on the
    development of immunotherapeutics for the treatment
    of autoimmune disorders, HIV/AIDS, cancers, and
    infectious diseases. Virax’s preventive HIV program is
    focused on a recombinant fowl pox virus designed to
    co-express genes for immunogenic but highly conserved parts of the HIV-1 virus in conjunction with a
    human cytokine (interferon gamma).
    www.iex.nl/forum/topic.asp?forum=228&...
  16. [verwijderd] 30 augustus 2006 13:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    *DJ Interim Data From Targeted Genetics' Phase I HIV/AIDS Vaccine Trial To Be Presented At Leading European AIDS Vaccine Meeting; Vaccine Candidate Well Tolerated; Modest Immune Response Observed In A Subset Of Patients>TGEN

    08/30/2006
    Dow Jones News Services
    (Copyright © 2006 Dow Jones & Company, Inc.)

    Dirk
  17. [verwijderd] 31 augustus 2006 13:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    DJ Vical Says Study Shows Broad T-Cell Immunity Against HIV Generated In Prime-Boost Vaccine Phase 1 Trial>VICL

    08/31/2006
    Dow Jones News Services

    Dirk
  19. [verwijderd] 31 augustus 2006 13:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ( BW)(MD-GENVEC)(GNVC) Data from Multiple Phase I Trials Incorporating
    GenVec Technology Presented at International AIDS Conference; Safety
    and Immunogenicity Data Presented by NIH VRC and HVTN

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    GAITHERSBURG, Md.--(BUSINESS WIRE)--Aug. 31, 2006--GenVec, Inc.
    (NASDAQ: GNVC) announced today that results from multiple Phase 1
    clinical trials were presented at the AIDS Vaccine 2006 Conference in
    Amsterdam this week. The HIV vaccine incorporating GenVec's
    adenovector-based technology was well tolerated, and results were
    consistent with previously reported data: induction of potent immune
    responses when the vaccine was used alone or in combination with a DNA
    primer vaccine. The results support the rationale for advanced
    clinical testing.
    In a study of the HIV vaccine incorporating GenVec's
    adenovector-based technology given to 40 volunteers as a single dose
    of either 1e10 Particle Units (PU) or 1e11 PU, both doses showed
    stimulation of T-cells against the multiple antigens contained in this
    vaccine. The study was presented by Dr. Larry Peiperl of University of
    California School of Medicine San Francisco, and the study was
    conducted by the HIV Vaccine Trials Network (HVTN).
    In a second study presented by Dr. Richard Koup of the Vaccine
    Research Center (VRC), National Institute of Allergy and Infectious
    Diseases, National Institutes of Health, cellular immune responses
    were analyzed in 14 volunteers given a DNA prime followed by a boost
    with the HIV vaccine incorporating GenVec's adenovector technology.
    Dr. Koup reported that these data indicate that the combination of
    priming and boosting produces more polyfunctional T-cells than either
    modality alone. "Polyfunctional T-cells are a hallmark of existing
    vaccines such as the effective smallpox vaccine and are also believed
    to be important for an effective HIV vaccine. A similar breadth of
    polyfunctional T-cells occurs in patients who have HIV but do not
    progress rapidly to AIDS," commented Dr. Rick King, GenVec's Senior VP
    of Research.
    In addition to the clinical presentations described above, there
    were presentations given by Drs. Gary Nabel and John Mascola of the
    VRC highlighting several next generation HIV vaccine approaches using
    GenVec adenovector technology.
    GenVec, Inc. is a biopharmaceutical company developing novel
    gene-based therapeutic drugs and vaccines. Additional information on
    GenVec and its portfolio of product candidates is available at
    www.genvec.com and in the company's various filings with the
    Securities and Exchange Commission.

    Statements herein relating to future financial or business
    performance, conditions or strategies and other financial and business
    matters, including expectations regarding future programs and studies,
    are forward-looking statements within the meaning of the Private
    Securities Litigation Reform Act. GenVec cautions that these
    forward-looking statements are subject to numerous assumptions, risks
    and uncertainties, which change over time. Factors that may cause
    actual results to differ materially from the results discussed in the
    forward-looking statements or historical experience include risks
    relating to the early stage of GenVec's product candidates under
    development; uncertainties relating to clinical trials; the timing and
    content of future U.S. Food and Drug Administration regulatory actions
    with respect to GenVec, its product candidates, or collaborators,
    risks relating to the commercialization, if any, of GenVec's proposed
    product candidates (such as marketing, regulatory, patent, product
    liability, supply, competition and other risks); dependence on the
    efforts of third parties; dependence on intellectual property; and
    risks that we may lack the financial resources and access to capital
    to fund our operations. Further information on the factors and risks
    that could affect GenVec's business, financial conditions and results
    of operations, are contained in GenVec's filings with the U.S.
    Securities and Exchange Commission (SEC), which are available at
    www.sec.gov. These forward-looking statements speak only as of the
    date of this press release, and GenVec assumes no duty to update
    forward-looking statements.

    CONTACT: GenVec, Inc.
    Investor Relations:
    Tricia J. Richardson, 240-632-5511
    trichardson@genvec.com
  20. [verwijderd] 31 augustus 2006 13:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0



    DJ Vical Says "Prime-Boost" Vaccine Effective In HIV Study

    DOW JONES NEWSWIRES

    Vical Inc. (VICL) said a "prime-boost" vaccine regimen tested in 40 HIV-uninfected subjects was safe, well-tolerated and "highly effective" in inducing T-cell immune responses during a Phase I trial.

    The San Diego-based pharmaceutical company said the trial involved priming an immune response with three doses of a plasmid DNA vaccine, which was based on Vical's proprietary DNA-delivery technology, and boosting the response with a single dose of adenoviral-vector vaccine given at a later date.

    Vical said the prime-boost vaccine regimen was effective in generating multiple types of HIV-specific T-cell immune responses.

    -Adam Kuczynski; 201-938-5400; AskNewswires@dowjones.com


    (END) Dow Jones Newswires

    08-31-06 0751ET



252 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.842
AB InBev 2 5.291
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.539
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.969
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.545
Aedifica 2 832
Aegon 3.257 320.149
AFC Ajax 537 7.018
Affimed NV 2 5.763
ageas 5.843 109.779
Agfa-Gevaert 13 1.864
Ahold 3.536 74.001
Air France - KLM 1.024 34.365
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.774
Alfen 12 16.616
Allfunds Group 3 1.223
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 339
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.767
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.405
AMG 965 126.191
AMS 3 73
Amsterdam Commodities 303 6.524
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.173
Apollo Alternative Assets 1 17
Apple 5 321
Arcadis 251 8.626
Arcelor Mittal 2.024 318.707
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.148
Aroundtown SA 1 179
Arrowhead Research 5 9.284
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.729
ASML 1.762 77.195
ASR Nederland 18 4.129
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.694
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 09 mei

    1. China handelsbalans april
    2. Argenx Q1-cijfers
    3. Hemelvaartsdag, Euronext Amsterdam regulier open
    4. Philips €0,85 ex-dividend
    5. DSM-Firmenich €2,50 ex-dividend
    6. Allfunds €0,0935 ex-dividend
    7. Coca-Cola EP €0,74 ex-dividend
    8. TKH €1,70 ex-dividend
    9. Bank of England - rentebesluit Onveranderd (5,25%)
    10. VS steunaanvragen - wekelijks
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda